Quarterly D&O Claims Trends: Q1 2017

Download PDF: Webinar Slides

The first quarter of 2017 witnessed a surge in Securities Class Action filings.  In addition, merger objection litigation continued at a relatively high rate. A significant driver of this has been the prominence of litigation involving companies in the pharmaceutical and biotech industries.

On April 27, a group of panelists to discussed some of the differences between the two industries and the drivers of litigation.

This is a free, one-hour webinar.

Panelists

The following panelists participated in the webinar:

• Kevin LaCroix, RT ProExec, a division of RT Specialty, and author of the D&O Diary
• Michael Piccione, SVP, Public D&O Division, Professional Lines, Allied World
• Caroline Bullerjahn, Partner, Goodwin Securities Litigation & White Collar Defense Group
• Jim Blinn, Executive Vice President, Information & Analytics Division, Advisen (moderator)

Webinar Topics

Topics discussed:

• Frequency and severity of securities suits in Q1 2017
• Suits by type
• Suits by sector
• Merger objection cases